Is IVF in Georgia Useful for Recurrent Miscarriage? A Reproductive Doctor’s Honest Analysis

Common Patient Misconception: Thinking Recurrent Miscarriage Can Only Be Investigated Domestically

In outpatient clinics, we often see couples with recurrent pregnancy loss (RPL) who have already undergone basic miscarriage etiology screening, including karyotyping of both partners, uterine cavity morphology, hormone panel, and antiphospholipid antibodies, all of which come back normal. They are diagnosed with "unexplained recurrent miscarriage" and are then told they can try IVF. However, many do not know that IVF itself does not directly solve the miscarriage problem — the step that truly reduces the miscarriage rate is preimplantation genetic testing for aneuploidies (PGT-A) combined with full-cycle endometrial immune assessment. Georgia, as an overseas assisted reproduction destination that has gained attention in recent years, has the maturity of its PGT-A technology, the legal permissibility of embryo screening, and the quality control standards of its genetic laboratories directly determining "whether IVF is useful."

Direct Answer to the Question: Useful, But with Strict Applicable Conditions

For couples with recurrent miscarriage, whether IVF in Georgia is effective needs to be judged in two situations:

• Effective situations: The cause is embryo chromosomal aneuploidy (accounting for 50%-70% of early miscarriages), female age ≥35, or a known chromosomal structural abnormality (e.g., balanced translocation). Georgia allows PGT-A full chromosome screening on blastocysts, enabling the selection of chromosomally normal embryos for transfer, theoretically reducing the miscarriage rate from 40%-50% to 10%-15%.
• Ineffective or limited effect situations: The cause of miscarriage is immune factors (e.g., abnormal NK cells, lack of blocking antibodies), coagulation abnormalities (antiphospholipid syndrome, protein S deficiency), uterine anatomical abnormalities (untreated septate uterus, adhesions), or endocrine diseases (thyroid dysfunction, luteal phase deficiency). These causes are not resolved by embryo screening and require targeted treatment or conditioning before considering transfer strategies.

Therefore, the premise for "useful" is: completing a comprehensive miscarriage etiology investigation at a Georgian reproductive center, confirming that the main issue lies at the embryo chromosome level, and that the local laboratory has PGT-A qualifications and good clinical data.

Why Recurrent Miscarriage? Etiological Stratification in Reproductive Medicine

The causes of recurrent miscarriage (usually defined as 2 or more consecutive spontaneous miscarriages) involve multiple levels:

Many patients only undergo the first level of basic examinations domestically, while hysteroscopy, comprehensive immune panels, and coagulation screening may be missed. If they go to Georgia for IVF directly with a diagnosis of "unexplained," the results may be counterproductive.

Doctor’s Perspective: The Value and Risks of Georgia

As a reproductive doctor, I believe Georgia’s advantages in the field of assisted reproduction are concentrated in the following points:

• Relaxed legal environment: Clear legal support for PGT-A, gender selection, and egg donation, with no age restrictions on embryo screening. This is not fully available in some domestic centers due to regulatory limitations.
• Lower cost compared to Europe/US: A single PGT-A test costs approximately $3,000-$5,000 USD, about 60% of the cost for the same test in the US.
• Variable laboratory quality: Not all Georgian reproductive centers have internationally certified embryology genetics laboratories. Some centers send biopsied samples to third-party companies or even overseas for testing, and the transport process may affect result accuracy.
• Insufficient data transparency: Many centers publish "transfer success rates" without distinguishing between first-visit patients and selected patients, and there is a significant difference between clinical pregnancy rates and live birth rates. For example, using donor eggs at age 50, one center’s live birth rate was only 12%, but they advertised a "pregnancy rate of 70%."

To determine whether a Georgian center is suitable for recurrent miscarriage patients, the core points are three: whether they offer a full set of miscarriage etiology tests (not just basic screening), whether PGT-A uses next-generation sequencing (NGS) with validated platforms, and whether they have an embryology genetic counselor to provide report interpretation.

The Most Easily Overlooked Details: Endometrial Immune Assessment and Implantation Window

A large number of recurrent miscarriage patients still miscarry even after transferring PGT-A normal embryos. The main reason is not embryo abnormality but poor endometrial receptivity or abnormal local immune microenvironment. Many Georgian centers recommend patients undergo hysteroscopy + endometrial biopsy + ERA (endometrial gene chip analysis) to determine the optimal transfer time and endometrial condition. However, there are three easily overlooked points:

• Chronic endometritis (CE): Can be detected by CD138 immunohistochemistry. Most Georgian centers do not actively screen for it; patients need to request it.
• Pre-transfer endometrial conditioning: Some centers use hormone replacement therapy (HRT) cycles, but if the patient has hypothyroidism or insulin resistance, these underlying conditions need to be controlled first. Entering the cycle directly increases the chance of failure.
• Timing of embryo biopsy: Blastocyst biopsy is performed on day 5 or 6. Patients with slow embryo development may have no blastocysts available for biopsy. In Georgia, some laboratories still attempt biopsy on slow-growing embryos, but even if these embryos are chromosomally normal, their subsequent implantation potential is very low.

The Easiest Pitfall: Choosing a "Guaranteed Success" Package Without Discrimination

Some Georgian agencies offer "recurrent miscarriage guaranteed success" packages, including 2-3 PGT-A transfer cycles, priced at 120,000-180,000 RMB. These packages usually have two traps:

• Does not include immune and coagulation treatment: If the patient has antiphospholipid syndrome requiring low molecular weight heparin or hydroxychloroquine, the package does not cover this cost. The patient buying heparin themselves may affect the transfer process.
• Conditional on "number of miscarriages": For example, requiring the patient to be ≤40 years old, AMH ≥1.2, and already diagnosed with chromosomal abnormalities. If it is discovered mid-process that the conditions are not met, the package automatically becomes invalid with no refund.

The correct approach is: first complete a full RPL etiology examination (costing about 10,000-20,000 RMB) either domestically or in Georgia, then choose a cycle with a clear diagnostic report and doctor’s strategy, rather than paying first and investigating later.

Specific Process and Timeline (Using Recurrent Miscarriage as an Example)

A complete Georgia IVF + PGT-A cycle, from preparation to transfer, typically takes 4-6 months. The timeline is as follows:

Note: Georgian law allows embryos to be stored in liquid nitrogen for 5 years. If no normal embryos are obtained in the first cycle, a second stimulation can be performed. However, recurrent miscarriage patients often already have compromised ovarian function, so it is necessary to assess in advance whether the number of retrieved eggs is sufficient.

Interpretation of Key Examination Indicators (Must-Check Items for Recurrent Miscarriage)

The following indicators are crucial for determining "whether IVF in Georgia is effective":

• AMH, FSH, Antral Follicle Count: Reflect ovarian reserve, determining whether enough eggs can be obtained for PGT-A. When AMH <0.5 ng/mL, the number of retrieved eggs may be less than 5, reducing the probability of forming blastocysts.
• Partner Karyotypes: If one partner has a balanced translocation, PGT-A needs to simultaneously use SNP or FISH to locate breakpoints; standard NGS may miss it.
• Sperm DNA Fragmentation Index (DFI): When DFI >30%, even if the embryo is chromosomally normal, the early miscarriage rate may still be elevated.
• Antiphospholipid Antibodies and β2-glycoprotein Antibodies: Positive results require treatment with low molecular weight heparin; otherwise, PGT-A normal embryos may still miscarry.
• NK Cell Activity and Endometrial CD138: Abnormalities suggest immune-related miscarriage, requiring IVIG or dexamethasone treatment before transfer.

If the above examinations have all been completed domestically and show that the main problem is embryo chromosomal aneuploidy (especially maternal age-related), then PGT-A in Georgia can indeed bring clear benefits to the patient. If the examination results mainly show immune and coagulation abnormalities, targeted treatment must first be completed domestically or locally before discussing IVF.

Frequently Asked Questions

• Q: My chromosomes are normal, but I still have recurrent miscarriages. Is PGT-A useful? A: Normal partner chromosomes do not guarantee normal embryo chromosomes. Older women have a higher error rate in oocyte meiosis, so PGT-A is still effective. However, if you are young (<35) and the proportion of aneuploidy in miscarried embryos is low, focus on endometrial and immune investigations.
• Q: Which is better for PGT-A, Georgia or the US? A: US laboratories have stricter quality control standards (e.g., CLIA certification), but costs are high. Some Georgian centers collaborate with German or Israeli laboratories, providing reliable data. It is recommended to choose a center with its own NGS laboratory and that can provide embryology genetic counseling.
• Q: What medications are needed for pregnancy support after transfer? A: Routine progesterone support is sufficient. Patients with immune abnormalities may need to add hydroxychloroquine, low molecular weight heparin, or IVIG. The specific plan should be based on examination results; not all Georgian doctors are familiar with immune pregnancy support protocols.
• Q: How long should I wait for a second attempt after one failure? A: At least 3 months. During this time, it is recommended to complete immune and endometrial examinations to avoid repeating the same mistakes.

Special Situation Management: Low AMH Combined with Recurrent Miscarriage

A common clinical challenge: patients aged 35-40, with AMH 0.6-1.0 ng/mL, and 2-3 recurrent miscarriages. These patients have low ovarian reserve and few retrieved eggs. If PGT-A is done directly, there may only be 1-2 blastocysts per cycle, ultimately resulting in no normal embryos for transfer. For this situation, some Georgian centers adopt a "cumulative cycle + oocyte cryopreservation" strategy: retrieve eggs 2-3 times, culture blastocysts together and biopsy, accumulate 4-5 embryos before doing PGT-A. However, this strategy has extremely high requirements for oocyte freezing technology and the embryologist’s blastocyst culture ability, and not all centers are suitable.

Risk Reminders

• PGT-A cannot detect all abnormalities: Mosaicism, uniparental disomy, microdeletions/duplications, etc. NGS testing also has about 1% false positives and false negatives. Comprehensive assessment combined with endometrial status is still needed before transfer.
• Difficulty handling overseas medical disputes: If ovarian hyperstimulation, egg retrieval infection, or laboratory accidents occur in Georgia, the process for seeking redress is complex. It is recommended to purchase insurance that includes medical transport.
• Language and cultural differences: Most Georgian reproductive centers have Russian or Georgian translators. Chinese translators are few and often agency staff, which may distort information. It is best to have an independent medical interpreter accompany key steps.

Doctor’s Advice

For recurrent miscarriage patients, do not treat "going to Georgia for IVF" as a last resort. The correct decision-making path is:

• First complete a three-level miscarriage etiology investigation domestically (chromosomes, uterine cavity, immunity, coagulation, endocrinology, infection).
• After identifying the main cause, evaluate whether Georgia’s technology can address that cause. If it is a chromosomal issue, you can go; if it is an immune issue, concurrent treatment is needed.
• When selecting a Georgian center, request their PGT-A live birth rate for the past year (stratified by age group and miscarriage cause), and ask to see laboratory quality control certificates.
• Do not believe vague data like "our success rate is 85%." Require calculation based on live birth rate per transfer cycle.
• Plan time in advance: reserve at least 4-6 months, including preliminary examinations and possible repeat stimulation cycles.

Finally, recurrent miscarriage is a complex clinical challenge, and no single technology can guarantee 100% success. IVF + PGT-A in Georgia is just a tool. The prerequisites for using it are accurate diagnosis, reasonable prognosis, and full risk awareness.